COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,158 Articles (22,703 medRxiv, 8,455 bioRxiv)

Most recent first Previous |  Page 149: Articles 1481-1490  | Next

The post-pandemic hospital and mortality burden of COVID-19 compared with influenza: A national cohort study in Denmark, May 2022 to June 2024
Bager, P., Bech Svalgaard, I., Kristensen Lomholt, F., Emborg, H.-D., Engbo Christiansen, L., Soborg, B., Hviid, A., Skafte Vestergaard, L.
10.1101/2024.09.26.24314428 — Posted: 2024-09-27
Cost-effectiveness analysis of COVID-19 mRNA XBB.1.5 Fall 2023 vaccination in the Netherlands
Zeevat, F., van der Pol, S., Westra, T., Beck, E., Postma, M. J., Boersma, C.
10.1101/2024.09.26.24314420 — Posted: 2024-09-27
The impact of the COVID-19 pandemic on mental health care utilization among people living with HIV: A real-world data study
Pasha, A., Qiao, S., Zhang, J., Cai, R., He, B., Yang, X., Liang, C., Weissman, S., Li, X.
10.1101/2024.09.26.24314443 — Posted: 2024-09-27
The coronavirus nsp14 exoribonuclease interface with the cofactor nsp10 is essential for efficient virus replication and enzymatic activity.
Grimes, S. L., Heaton, B. E., Anderson, M. L., Burke, K. N., Stevens, L. J., Lu, X., Heaton, N. S., Denison, M. R., Anderson-Daniels, J.
10.1101/2024.09.26.615217 — Posted: 2024-09-26
Human NK cell responses to the SARS-CoV-2 Spike269-277 peptide YLQPRTFLL
Bilev, E., Schiele, S., Foglietta, B., Ljunggren, H.-G., Hammer, Q.
10.1101/2024.09.26.613632 — Posted: 2024-09-26
Effect of Immunoadsorption on clinical presentation and immune alterations in COVID-19-associated ME/CFS
Anft, M., Wiemers, L., Rosiewicz, K., Doevelaar, A., Skrzypczyk, S., Kurek, J., Kaliszczyk, S., Seidel, M., Stervbo, U., Seibert, F. S., Westhoff, T. H., Babel, N.
10.1101/2024.09.25.24314345 — Posted: 2024-09-26
Betacoronaviruses Differentially Activate the Integrated Stress Response to Optimize Viral Replication in Lung Derived Cell Lines
Renner, D. M., Parenti, N. A., Weiss, S. R.
10.1101/2024.09.25.614975 — Posted: 2024-09-26
Differential Kinetics of SARS-CoV-2 Proteases Revealed by a Dual-Color, BRET-based Protease Biosensor, DuProSense
Fatima, A., Geethakumari, A. M., Uddin, S. M., Biswas, K. H.
10.1101/2024.09.26.615113 — Posted: 2024-09-26
SARS-CoV-2 ORF3a Protein Impairs Syncytiotrophoblast Maturation, Alters ZO-1 Localization, and Shifts Autophagic Pathways in Trophoblast Cells and 3D Organoids
Kumar, D., Karvas, R. M., Jones, B., McColl, E., Diveley, E., Jash, S., Sharma, S., Kelly, J., Theunissen, T., Mysorekar, I. U.
10.1101/2024.09.25.614931 — Posted: 2024-09-25
Inflammation cellular platform (INCEPLAT) for testing anti-inflammatory compounds for SARS-CoV-2
LOPEZ-AYLLON, B. D., MENDOZA-GARCIA, L., DE LUCAS-RIUS, A., GARCIA-GARCIA, T., FERNANDEZ-RODRIGUEZ, R., ROMERO-GUILLEN, A., Serrat, J., Zuniga, S., REDONDO, N., Siles-Lucas, M., GARRIDO, J. J., MONTOYA, M.
10.1101/2024.09.25.614910 — Posted: 2024-09-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).